# Long-Term Melatonin Use Linked to Dramatically Higher Heart Failure Risk
A large preliminary study found that people taking melatonin chronically developed heart failure at roughly twice the rate of non-users over a five-year period. The research adds caution to the widespread use of melatonin supplements, which millions of Americans take nightly without medical oversight.
The study examined patients with chronic insomnia who used melatonin long term and tracked their cardiovascular outcomes. Researchers discovered approximately a 90% increased risk of heart failure development in this population compared to controls. The findings emerged from analysis of health records spanning five years, providing a substantial dataset for preliminary conclusions.
Melatonin, a hormone naturally produced by the pineal gland, regulates sleep-wake cycles. Over the past two decades, synthetic melatonin supplements have become ubiquitous in drugstores and online retailers, marketed as safe sleep aids without prescription requirements. Americans spend roughly $400 million annually on melatonin products. Usage has exploded among all age groups, from children to older adults, often without consulting physicians.
The study's authors emphasize their findings show association, not causation. The research cannot definitively prove melatonin directly damages the heart. Multiple confounding factors could explain the elevated risk. People with chronic insomnia may already carry higher cardiovascular disease risk from underlying metabolic conditions, stress, or sleep deprivation itself. Long-term melatonin users might differ systematically from non-users in unmeasured ways affecting heart health.
Nevertheless, the magnitude of the risk increase warrants investigation. Previous research has suggested melatonin affects blood vessel function and inflammation, both central to heart failure development. Animal studies show melatonin influences cardiac muscle contractility. The mechanisms connecting melatonin to heart disease remain incompletely understood, but biological plausibility exists.
Current FDA regulations classify melatonin as a dietary supplement rather than medication, meaning manufacturers face minimal approval hurdles. The agency does not require manufacturers to demonstrate long-term safety before products reach shelves. Consumers encounter labels suggesting melatonin poses no risks, despite limited evidence supporting indefinite use at high doses.
The study raises urgent questions for sleep medicine. Physicians treating insomnia patients currently lack clear guidance on melatonin safety thresholds. Typical recommended doses range from 0.5 to 10 milligrams nightly, but retail products often contain 5 to 20 times physiological melatonin concentrations. Whether standard doses carry the same risk as higher quantities remains unknown.
Patients currently using melatonin should not abruptly discontinue without medical consultation. Withdrawal effects and rebound insomnia can occur with sudden cessation. Instead, individuals taking melatonin long term should discuss cardiovascular risk with their physicians, particularly those with existing heart disease or risk factors.
Researchers now need randomized controlled trials examining melatonin's cardiac safety directly. Such studies would clarify whether the observed association reflects causation. Mechanistic research exploring how melatonin affects heart tissue could identify vulnerable populations requiring alternative sleep treatments. Until then, the preliminary findings counsel caution regarding melatonin's long-term use, particularly among those already at cardiovascular risk.